End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI). This is an ASCO Meeting Abstract from the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results